Cargando…

Capecitabine in the treatment of metastatic renal cell carcinoma

To evaluate the therapeutic effects and systemic toxicities of a capecitabine-based home therapy regimen in patients with metastatic renal cell carcinoma, 30 patients were enrolled in a phase II clinical trial. Treatment consisted of oral capecitabine combined with subcutaneous recombinant human int...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oevermann, K, Buer, J, Hoffmann, R, Franzke, A, Schrader, A, Patzelt, T, Kirchner, H, Atzpodien, J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363511/ https://www.ncbi.nlm.nih.gov/pubmed/10944596 http://dx.doi.org/10.1054/bjoc.2000.1340

Ejemplares similares

Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma
por: Hoffmann, R, et al.
Publicado: (1999)

Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma
por: Wittke, F, et al.
Publicado: (1999)

Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
por: Hoffmann, R., et al.
Publicado: (1998)

IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial
por: Atzpodien, J, et al.
Publicado: (2001)

Elevated serum levels of S100 and survival in metastatic malignant melanoma.
por: Buer, J., et al.
Publicado: (1997)

Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma.
por: Franzke, A., et al.
Publicado: (1998)

Metastatic renal carcinoma comprehensive prognostic system
por: Atzpodien, J, et al.
Publicado: (2003)

An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma
por: Royston, P, et al.
Publicado: (2006)

Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide
por: Kraemer, Anja, et al.
Publicado: (2009)

CXCR4/CXCL12 expression and signalling in kidney cancer
por: Schrader, A J, et al.
Publicado: (2002)

Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma
por: Waters, J S, et al.
Publicado: (2004)

Interferon-α resistance in renal carcinoma cells is associated with defective induction of signal transducer and activator of transcription 1 which can be restored by a supernatant of phorbol 12-myristate 13-acetate stimulated peripheral blood mononuclear cells
por: Brinckmann, A, et al.
Publicado: (2002)

Oral Capecitabine Achieves Response in Metastatic Eccrine Carcinoma
por: Larson, Kristian, et al.
Publicado: (2018)

Capecitabine in hormone-resistant metastatic prostatic carcinoma – a phase II trial
por: Morant, R, et al.
Publicado: (2004)

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
por: Pronk, L C, et al.
Publicado: (2000)

Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma
por: Park, Se Hoon, et al.
Publicado: (2006)

Immunochemotherapy with interleukin-2, interferon- α and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study
por: Herpen, C M L van, et al.
Publicado: (2000)

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2010)

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
por: Wist, E. A., et al.
Publicado: (2012)

Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option
por: Meulendijks, D, et al.
Publicado: (2014)

Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer
por: Si, W., et al.
Publicado: (2013)

Capecitabine Monotherapy as Palliative Treatment for Patients with Recurrent/Metastatic Nasopharyngeal Cancer
por: Alshamsan, Bader, et al.
Publicado: (2022)

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients
por: LIANG, XU, et al.
Publicado: (2015)

Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2011)

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
por: Wilbur, H. Catherine, et al.
Publicado: (2023)

Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’
por: Molina-Garrido, M J, et al.
Publicado: (2011)

Analysis of the TSC1and TSC2genes in sporadic renal cell carcinomas
por: Parry, L, et al.
Publicado: (2001)

Rapid deterioration in quality of life during interleukin-2- and α-interferon-based home therapy of renal cell carcinoma is associated with a good outcome
por: Atzpodien, J, et al.
Publicado: (2003)

Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer
por: García-Alfonso, P, et al.
Publicado: (2010)

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
por: Saura, Cristina, et al.
Publicado: (2021)

Efficacy of Bevacizumab-Capecitabine in Combination for the First-Line Treatment of Metastatic Breast Cancer
por: Dyar, Stephen, et al.
Publicado: (2011)

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours
por: Medley, L, et al.
Publicado: (2011)

Treatment of Refractory Metastatic Renal Cell Carcinoma
por: Vento, Joseph A., et al.
Publicado: (2022)

Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma
por: Assersohn, L, et al.
Publicado: (1999)

Regular use of analgesics is a risk factor for renal cell carcinoma
por: Gago-Dominguez, M, et al.
Publicado: (1999)

The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer
por: Almond, J, et al.
Publicado: (2007)

Chromosomal alterations in the clonal evolution to the metastatic stage ofquamous cell carcinomas of the lung
por: Petersen, S, et al.
Publicado: (2000)

Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer
por: Awada, A.H., et al.
Publicado: (2022)

Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
por: Atzpodien, J, et al.
Publicado: (2005)

Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization
por: Stassar, M J J G, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_qkttk7bra70hmpbs20pd3hb3v0